ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
63,611.10
-1.02%
S&P 500
5,732.93
0.00%
Dow Jones
42,208.22
0.00%
US Dollar vs Yen
144.2095
0.87%
Brent Oil
73.46
-1.48%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Galmed Pharmaceuticals Ltd (GLMD)

  7. Galmed Pharmaceuticals Ltd (GLMD) ニュース

GLMD

Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:GLMD
日付受信時刻ニュースソース見出しコード企業名
2024/09/2521 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/2521 : 00PR Newswire (US)Galmed publishes Results from Aramchol Phase 3 Open Label part in HepatologyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/2105 : 46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/2103 : 18Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/2103 : 17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/1920 : 13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/1920 : 00PR Newswire (US)Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic DiseasesNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/1705 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/1705 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/1013 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/09/1005 : 30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/08/3105 : 25Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/08/3105 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/08/2905 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/08/2805 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/07/1121 : 50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/06/0605 : 16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/05/3105 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/04/0506 : 06PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/03/1522 : 00PR Newswire (US)Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/02/1504 : 14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2024/02/1306 : 15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2023/11/3014 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2023/11/2306 : 48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2023/11/2106 : 37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2023/11/2106 : 32PR Newswire (US)Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2023/11/0205 : 15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2023/09/2621 : 51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
2023/09/2621 : 30PR Newswire (US)Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
2023/09/2305 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:GLMD

最近閲覧した銘柄

USOTC
DROOF
Deliveroo (PK)
USOTC
AACTF
Aurora Solar Technologies (PK)
EU
FR2CIBFS2199
Credit Agricole CIB FCIA...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有